Zsírmáj (MASLD/MASH): vizsgálatok itt: Ausztria
9 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- No phaseNot yet taking people in AusztriaPersonalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD
- Where
- Vienna
- Életkor
- 18 év to 80 év
- People
- 174
- Run by
- Medical University of Vienna
See details and how to joinNCT07914829 - 3. fázisTaking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Graz, Linz, Vienna, Wels
- Életkor
- 18 év and over
- People
- 1800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - 3. fázisTaking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Graz, Linz, Vienna, Wels
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Graz, Innsbruck, Klagenfurt Am Woerthersee, St. Poelten, Wels
- Életkor
- 18 év to 80 év
- People
- 1350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - 3. fázisNot yet taking people in AusztriaA pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
- Where
- Graz, Klagenfurt Am Woerthersee, Vienna
- Életkor
- 18 év and over
- People
- 382 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00 - 3. fázisNot yet taking people in AusztriaA study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
- Where
- Graz, Klagenfurt Am Woerthersee, Vienna
- Életkor
- 18 év and over
- People
- 69 worldwide
- Run by
- Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00 - 3. fázisTaking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- Graz, Salzburg, Vienna, Wiener Neustadt
- Életkor
- 18 év and over
- People
- 4500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - 3. fázisTaking peopleA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- Where
- Graz, Innsbruck, Klagenfurt Am Woerthersee, Vienna
- Életkor
- 18 év to 75 év
- People
- 1250 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00 - No phaseTaking peopleCold-induced Brown Fat Activation and Hepatic Steatosis
- Where
- Vienna
- Életkor
- 18 év to 50 év
- People
- 26
- Run by
- Medical University of Vienna
See details and how to joinNCT03811236